Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Histologically confirmed diagnosis of GIST that is unresectable and/or metastatic
Radiological confirmation of disease progression or intolerance to imatinib therapy at a any dose
At least one measurable site of disease on CT scan at Visit-2
WHO Performance Status of 0, 1 or 2 at Visit-2
Patients must have normal organ, electrolyte, and marrow function at Visit-1 and Visit-2
Prior treatment with nilotinib or any other tyrosine kinase inhibitors except imatinib.
Treatment with any cytotoxic and/or investigational cytotoxic drug ≤ 4 weeks
Prior or concomitant malignancies other than GIST
Impaired cardiac function at Visit-1 or 2
Patients with severe and/or uncontrolled concurrent medical disease
Use of therapeutic coumarin derivatives
Use of any medications that prolong the QT interval
Use of CYP3A4 inhibitors
Patients who have undergone major surgery ≤ 2 weeks prior to Visit-1 or who have not recovered from side effects of such surgery
Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation < 2 weeks prior to Visit-1 or who have not recovered from side effects of such therapy
Other protocol-defined inclusion/exclusion criteria may apply